Jump to content

Michael Jeltsch

From Wikipedia, the free encyclopedia

Michael Jeltsch (born July 28, 1969, Hemer/NW, Germany) is a German-Finnish researcher in the field of Biochemistry. He is an associate professor at the University of Helsinki,[1] Finland. He has more than 70 publications.[2] Jeltsch was the first to show that VEGF-C and VEGF-D are the principal growth factors for the lymphatic vasculature[3][4][5] and his research focuses on cancer drug targets and lymphangiogenesis. He has also contributed to other seminal publications in cell biology[6][7] with transgenesis, protein engineering, recombinant production and purification. In 2006, he developed a synthetic super-VEGF, using a library of VEGF hybrid molecules using a novel, non-random DNA family shuffling method.[8]

Jeltsch completed his graduation, postgraduation, and postdoc at Molecular/Cancer Biology Lab, University of Helsinki, Helsinki, Finland. He worked as a researcher at Lymphatix Ltd. (now Ark Therapeutics) via Licentia Ltd., Helsinki, Finland (April 2006 – January 2007) and at Circadian Technologies via Vegenics Ltd. via Licentia Ltd., Helsinki, Finland (February 2007 – December 2011), where he was involved in the research on VEGF-C and VEGF-D as drugs and drug targets.[9][10][11] He worked as a Postdoctoral Fellow at the Wihuri Research Institute, Helsinki, Finland from January 2013 to August 2013. Since 2013, he is a Group leader and since 2020 Associate Professor for Pharmaceutical Protein Drug Research at the Faculty of Pharmacy at University of Helsinki, Helsinki, Finland. The Jeltsch lab is affiliated with the Drug Development Program and the Individualized Drug Therapy Research Program.[12]

He was awarded Medix Prize by the Minerva Foundation Institute for Medical Research for best biomedical publication of the year in Finland in March 1997. In 2003, he received the Mandatum Prize for the best PhD thesis in the field of biotechnology in Finland. In 2015, he received the “Best Paper Award” in the category of Basic Science by Circulation, the journal of the American Heart Association for his 2014 work,[13] in which he identified the molecular mechanism behind Hennekam syndrome.[14]

References

[edit]
  1. ^ "Michael Jeltsch, University of Helsinki". research.med.helsinki.fi. 13 February 2017.
  2. ^ "Publications". researcherid.com.
  3. ^ Jeltsch, M; Kaipainen, A; Joukov, V; Meng, X; Lakso, M; Rauvala, H; Swartz, M; Fukumura, D; Jain, RK; Alitalo, K (30 May 1997). "Hyperplasia of lymphatic vessels in VEGF-C transgenic mice". Science. 276 (5317): 1423–5. doi:10.1126/science.276.5317.1423. PMID 9162011.
  4. ^ Oh, SJ; Jeltsch, MM; Birkenhäger, R; McCarthy, JE; Weich, HA; Christ, B; Alitalo, K; Wilting, J (1 August 1997). "VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane". Developmental Biology. 188 (1): 96–109. doi:10.1006/dbio.1997.8639. PMID 9245515.
  5. ^ Achen, MG; Jeltsch, M; Kukk, E; Mäkinen, T; Vitali, A; Wilks, AF; Alitalo, K; Stacker, SA (20 January 1998). "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)". Proceedings of the National Academy of Sciences of the United States of America. 95 (2): 548–53. Bibcode:1998PNAS...95..548A. doi:10.1073/pnas.95.2.548. PMC 18457. PMID 9435229.
  6. ^ Mandriota, SJ; Jussila, L; Jeltsch, M; Compagni, A; Baetens, D; Prevo, R; Banerji, S; Huarte, J; Montesano, R; Jackson, DG; Orci, L; Alitalo, K; Christofori, G; Pepper, MS (15 February 2001). "Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis". The EMBO Journal. 20 (4): 672–82. doi:10.1093/emboj/20.4.672. PMC 145430. PMID 11179212.
  7. ^ Gerhardt, H; Golding, M; Fruttiger, M; Ruhrberg, C; Lundkvist, A; Abramsson, A; Jeltsch, M; Mitchell, C; Alitalo, K; Shima, D; Betsholtz, C (23 June 2003). "VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia". The Journal of Cell Biology. 161 (6): 1163–77. doi:10.1083/jcb.200302047. PMC 2172999. PMID 12810700.
  8. ^ Jeltsch, M; Karpanen, T; Strandin, T; Aho, K; Lankinen, H; Alitalo, K (28 April 2006). "Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns". The Journal of Biological Chemistry. 281 (17): 12187–95. doi:10.1074/jbc.m511593200. PMID 16505489.
  9. ^ "Patent". patft1.uspto.gov.
  10. ^ "Patent". patft1.uspto.gov.
  11. ^ "Patent". patft1.uspto.gov.
  12. ^ "Affiliation". lab.jeltsch.org.
  13. ^ Jeltsch, M; Jha, SK; Tvorogov, D; Anisimov, A; Läppänen, V-M; Holopainen, T; Kivelä, R; Ortega, S; Kärpänen, T; Alitalo, K (19 February 2014). "CCBE1 Enhances Lymphangiogenesis via A Disintegrin and Metalloprotease With Thrombospondin Motifs-3–Mediated Vascular Endothelial Growth Factor-C Activation". Circulation. 129 (19): 1962–71. doi:10.1161/circulationaha.113.002779. PMID 24552833.
  14. ^ "The winner of the "Best Paper Award" of Circulation - Michael Jeltsch". med.helsinki.fi. 10 June 2016.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Michael_Jeltsch&oldid=1133136485"